Abstract
Neuroinflammation is involved in various central nervous system (CNS) disorders, including brain infections, ischemia, trauma, stroke, and degenerative CNS diseases. In the CNS inflammation, secretory phospholipase A&sub2;-IIA (sPLA&sub2;-IIA) acts as a mediator, resulting in the generation of the precursors of pro-inflammatory lipid mediators, such as prostaglandins (PGs) and leukotrienes (LTs). However, the role of sPLA&sub2;-IIA in neuroinflammation is more complicated and remains unclear yet. In the present study, we investigated the effect of sPLA&sub2;-IIA inhibition by specific inhibitor SC-215 on the inflammation in LPS-induced mice cerebral cortex and primary astrocytes. Our results showed that the inhibition of sPLA&sub2;-IIA alleviated the release of PGE&sub2; by suppressing the activation of ERK1/2, cPLA&sub2;α, COX-2 and mPGES-1. These findings demonstrated that sPLA&sub2;-IIA showed the potential to regulate the neuroinflammation in vivo and in vitro, indicating that sPLA&sub2;-IIA might be a novel target for the treatment of acute neuroinflammation.